Friday, March 07, 2008

Treatment compliance - second generation antipsychotics fail to live up to their promise

Long-term maintenance anti-psychotic treatment remains the most reliable means of preventing relapses, minimizing mortality and illness and ensuring independent living in people being treated for schizophrenia. However, treatment non-adherence remains a significant concern with the reported rates of non-adherence varying between 24-90% depending on the kind of patients being treated. One of the causes of non-adherence to treatment is the side effects of drugs. Second generation anti-psychotics were thought to have at least partially overcome this problem as they have fewer side effects than earlier drugs. However, a review of studies into compliance with treatment for schizophrenia has found that 'the data have failed to substantiate the notion that novel antipsychotic drug use leads to improved medication compliance and favourable clinical outcomes'.

Voruganti, Lakshmi P., Baker, Laura K. and Awad, George A. - New generation antipsychotic drugs and compliance behaviour Current Opinion in Psychiatry March 2008, 21(2), 133-139

No comments: